Cargando…

Antitumor effects of anlotinib in thyroid cancer

There is no effective treatment for patients with poorly differentiated papillary thyroid cancer or anaplastic thyroid cancer (ATC). Anlotinib, a multi-kinase inhibitor, has already shown antitumor effects in various types of carcinoma in a phase I clinical trial. In this study, we aimed to better u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruan, Xianhui, Shi, Xianle, Dong, Qiman, Yu, Yang, Hou, Xiukun, Song, Xinhao, Wei, Xi, Chen, Lingyi, Gao, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215907/ https://www.ncbi.nlm.nih.gov/pubmed/30139768 http://dx.doi.org/10.1530/ERC-17-0558

Ejemplares similares

LDHA induces EMT gene transcription and regulates autophagy to promote the metastasis and tumorigenesis of papillary thyroid carcinoma
por: Hou, Xiukun, et al.
Publicado: (2021)

KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway
por: Zhang, Wei, et al.
Publicado: (2022)

PARP inhibitor shuts down the global translation of thyroid cancer through promoting Pol II binding to DIMT1 pause
por: Hou, Xiukun, et al.
Publicado: (2023)

BRMS1 downregulation is a poor prognostic biomarker in anaplastic thyroid carcinoma patients
por: Wu, Yu, et al.
Publicado: (2019)

Rtfc (4931414P19Rik) Regulates in vitro Thyroid Differentiation and in vivo Thyroid Function
por: Yu, Yang, et al.
Publicado: (2017)

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature
por: Zhang, Xi, et al.
Publicado: (2021)

Intratumoral injection of anlotinib hydrogel enhances antitumor effects and reduces toxicity in mouse model of lung cancer
por: Gao, Qin, et al.
Publicado: (2020)

Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib
por: Hu, Linfei, et al.
Publicado: (2022)

Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer
por: Han, Dong, et al.
Publicado: (2022)

Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer
por: Wu, Jiajun, et al.
Publicado: (2023)

MicroRNA-940 restricts the expression of metastasis-associated gene MACC1 and enhances the antitumor effect of Anlotinib on colorectal cancer
por: Wang, Yan, et al.
Publicado: (2019)

Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma
por: Luo, Mei, et al.
Publicado: (2021)

Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer
por: Zhang, Jun, et al.
Publicado: (2021)

Identification of potential pathogenic candidates or diagnostic biomarkers in papillary thyroid carcinoma using expression and methylation profiles
por: Wei, Songfeng, et al.
Publicado: (2019)

Aurora kinase a promotes the progression of papillary thyroid carcinoma by activating the mTORC2-AKT signalling pathway
por: Zhao, Zewei, et al.
Publicado: (2022)

Potential Antitumor Effect of Harmine in the Treatment of Thyroid Cancer
por: Ruan, Shu, et al.
Publicado: (2017)

Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis
por: Zhen, Hongchao, et al.
Publicado: (2023)

The efficacy and safety of anlotinib treatment for advanced lung cancer
por: Shao, Lan, et al.
Publicado: (2019)

High expression of NUCB2 promotes papillary thyroid cancer cells proliferation and invasion
por: Zhao, Jingzhu, et al.
Publicado: (2019)

Early Combined SHP2 Targeting Reverses the Therapeutic Resistance of Vemurafenib in Thyroid Cancer
por: Ma, Weike, et al.
Publicado: (2023)

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
por: Sun, Yongkun, et al.
Publicado: (2016)

Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer
por: Xia, Xinhang, et al.
Publicado: (2022)

Case report of severe pneumothorax due to lung cancer treated with anlotinib
por: Lu, Haowei, et al.
Publicado: (2023)

Serum Eicosanoids Metabolomics Profile in a Mouse Model of Renal Cell Carcinoma: Predicting the Antitumor Efficacy of Anlotinib
por: Du, Ping, et al.
Publicado: (2022)

Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
por: Jia, Wenqing, et al.
Publicado: (2022)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
por: Liu, Zhujun, et al.
Publicado: (2022)

Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway
por: Meng, Xiangrui, et al.
Publicado: (2020)

Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer
por: Yuan, Meng, et al.
Publicado: (2022)

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
por: Hu, Nanlin, et al.
Publicado: (2021)

Surgical resection following therapy with anlotinib in locally advanced papillary thyroid carcinoma: a case description
por: Zhang, Jing, et al.
Publicado: (2023)

Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma
por: Wang, Zhi‐Ming, et al.
Publicado: (2020)

Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
por: Dai, Shuang, et al.
Publicado: (2022)

Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
por: Chi, Yihebali, et al.
Publicado: (2023)

Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study
por: Zhao, Jingzhu, et al.
Publicado: (2022)

Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients
por: Zheng, Xiangqian, et al.
Publicado: (2019)

Diagnosis and treatment of ectopic thyroid carcinoma: A case report and literature review
por: Fu, Guiming, et al.
Publicado: (2022)

Successful treatment of advanced ovarian cancer with anlotinib: a case report
por: Zhang, Ping, et al.
Publicado: (2020)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer
por: Su, Xi, et al.
Publicado: (2020)

The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study
por: Zheng, Hao-Ran, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9fq5bm0mvjfdan8tu4b7a9h5jc